Clinical Trials Logo

Non-valvular Atrial Fibrillation clinical trials

View clinical trials related to Non-valvular Atrial Fibrillation.

Filter by:

NCT ID: NCT03087487 Completed - Clinical trials for Non-Valvular Atrial Fibrillation

Clinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial Fibrillation

ARISTOPHANES
Start date: January 1, 2012
Phase:
Study type: Observational

The primary objectives of this study are to compare the risk of major bleeding and stroke/systemic embolism (SE) events among oral anticoagulant (OAC)-naïve non-valvular atrial fibrillation (NVAF) patients initiating OAC warfarin or apixaban or dabigatran or rivaroxaban treatment.

NCT ID: NCT03002740 Withdrawn - Clinical trials for Non-valvular Atrial Fibrillation

Bleeding Events and Oral Anticoagulant Treatment in Non-Valvular Atrial Fibrillation

Start date: January 31, 2016
Phase:
Study type: Observational

In a population of patients with non-valvular atrial fibrillation (NVAF), and treated with oral anticoagulants (OAC) in routine clinical practice in England, this study will describe patients treated with each OAC, and to estimate and compare event rates of treatment discontinuation, bleeding, and healthcare resource utilisation (HCRU) across OAC treatments.

NCT ID: NCT02937025 Not yet recruiting - Stroke Clinical Trials

Study of Safety and Efficacy of a Left Atrial Appendage Occulder

Start date: January 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This study mainly evaluated the feasibility and safety of a kind of Left Atrial Appendage Occluders which is to prevent ischemic stroke caused by nonvalvular atrial fibrillation (AF)

NCT ID: NCT02756481 Completed - Clinical trials for Non-Valvular Atrial Fibrillation

Local Adaptation of Cost Effectiveness Model for Apixaban Atrial Fibrillation Indication - Venezuela

Start date: October 2013
Phase: N/A
Study type: Observational

To characterize treatment patterns and healthcare resource utilization among adults diagnosed with non-valvular atrial fibrillation (NVAF) from the private setting in Venezuela.

NCT ID: NCT02654470 Completed - Clinical trials for Non-valvular Atrial Fibrillation

Watchman FLX Left Atrial Appendage Closure Device Post Approval Study ( Europe Only)

Start date: July 16, 2019
Phase:
Study type: Observational

Watchman FLX Left Atrial Appendage Closure Device Post Approval Study

NCT ID: NCT02502396 Completed - Cancer Clinical Trials

Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center

Start date: September 28, 2015
Phase:
Study type: Observational

The primary objective of this study is to evaluate the practice patterns of rivaroxaban usage invenous-thromboembolism (VTE) and non-valvular atrial fibrillation (NVAF) in cancer patients. The secondary objectives are to evaluate outcomes such as recurrent VTE, stroke and bleeding for cancer patients on rivaroxaban.

NCT ID: NCT02488421 Completed - Clinical trials for Non-valvular Atrial Fibrillation

Real Evidence of Anticoagulation Treatment in Non-valvular Atrial Fibrillation in Germany, UK and France: REACT-AF2

REACT-AF2
Start date: June 2014
Phase: N/A
Study type: Observational

The purpose of this study is to determine and compare the persistence rate of newly prescribed apixaban, rivaroxaban, dabigatran and VKAs in patients with NVAF.

NCT ID: NCT02422602 Completed - Clinical trials for Non-valvular Atrial Fibrillation

Better Adherence With New Oral Anticoagulant in Atrial Fibrillation : Effectiveness of a Personalized Education Program

MONACO
Start date: November 26, 2013
Phase: N/A
Study type: Interventional

This study is multicentric, single-blind, and interventional with a randomization into two parallel arm, between a standard of care information and an additional information of the patient, with a 12 month follow up. The aim of this study is to evaluate the effectiveness of a personalized information program versus information provided from standard of care in patients taking Xarelto for Stroke Prevention in Atrial Fibrillation.

NCT ID: NCT02362659 Completed - Clinical trials for Non-valvular Atrial Fibrillation

Antithrombotic Strategy Variability In ATrial Fibrillation and Obstructive Coronary Disease Revascularized With PCI - The AVIATOR 2 Registry

Start date: April 2015
Phase:
Study type: Observational [Patient Registry]

The purpose of this observational registry was to compare the safety and efficacy of an antithrombotic regimen comprising one single antiplatelet agent plus an oral anti-thrombotic versus those consisting of DAPT alone or DAPT plus oral antithrombotic therapy. This registry assessed whether the antithrombotic therapy intensity would vary positively with physician perceived ischemic risk at the time of percutaneous coronary intervention (PCI), and whether an inverse association would be observed with perceived bleeding risk. This study also evaluated the physician use of objective benefit-risk assessment scores and their influence on prescription of antithrombotic therapy in atrial fibrillation (AF) patients undergoing PCI. Additionally the study investigated whether patient perceived relevance and accessibility of anti-platelet and anticoagulant treatment regiments would predict treatment adherence and whether non-adherence would independently influence outcome. Approximately 514 subjects with non-valvular AF undergoing all-comer PCI were enrolled at 11 sites in North America and Europe. Follow-up was done via telephone by trained research coordinators at each participating site at 30 days, 6 months and 12 months.

NCT ID: NCT02222090 Recruiting - Atrial Fibrillation Clinical Trials

Therapy With New Oral Anticoagulants

Start date: July 2014
Phase: N/A
Study type: Observational

The aim of the present registry is to characterize and follow patients prospectively and retrospectively with renal impairment who have been prescribed apixaban for the prevention of stroke in atrial fibrillation, with a comparison to the characteristics and outcomes associated with warfarin therapy in this population.